Treatment for neovascular age-related macular degeneration (nAMD) has evolved rapidly over the past decade, during which pivotal trials have established the efficacy of vascular endothelial growth factor (VEGF) inhibitor therapy in this indication [1–3]. This evidence concerns the gene VEGFA and wet macular degeneration.